Skip to main content
. 2018 Mar 14;7:31. doi: 10.1038/s41426-018-0038-9

Fig. 4.

Fig. 4

a The pooled prevalence of MDR in A. baumannii isolates from 2006–2016 in OECD and non-OECD countries. b The pooled crude odds ratios between antibiotic resistance in A. baumannii infections and prior exposure to any antibiotic. c The pooled crude odds ratios between antibiotic resistance in A. baumannii infections and ICU or non-ICU hospitalization. PIP-TAZ piperacillin-tazobactam, AMP-SUL ampicillin-sulbactam